A method to analyze the glycan shield on HIV's protective outer glycoprotein has been developed as a potential HIV vaccine candidate, report scientists. HIV is a master of disguise. The virus uses a ...
Duke Human Vaccine Institute (DHVI) investigators used a technique called time-resolved, temperature-jump (TR, T-Jump) small-angle x-ray scattering (SAXS) to capture the spectacularly brief moment ...
Scientists hope that their new method of “fingerprinting” the shields of sugar molecules that HIV surrounds itself with to evade the immune system will improve and speed up the development of ...
Data shows how antibodies bind to V1/V2 domain. Scientists report on the structure of the HIV-1 gp120 glycoprotein’s V1/V2 domain and how a broadly neutralizing antibody binds to the structure and ...
Scientists have made another important advance in HIV vaccine design. The development was possible thanks to previous studies showing the structures of a protein on HIV’s surface, called the envelope ...
One of the main challenges of developing an HIV-1 vaccine lies in eliciting immune responses that can overcome the antigenic variability exhibited by HIV. Most HIV-1 vaccine development has focused on ...
The first trial of the efficacy of a human immunodeficiency virus (HIV)-l vaccine was conducted in North America and The Netherlands between 1998 and 2003. This multicenter, randomized, ...
A novel approach to HIV vaccine development has proved successful in stabilizing the HIV-1 surface protein Env and produces an effective anti-HIV immune response. A novel approach to HIV vaccine ...
Viruses need host cells, and viral pathogens have many different ways to infect those hosts. Scientists have revealed a rapid movement made by a small molecule called a glycoprotein on the surface of ...
Dendritic cell (DC)-specific intercellular adhesion molecule 3 (ICAM-3) grabbing nonintegrin (DC-SIGN), a recently discovered type II transmembrane protein on DCs with a C-type lectin extracellular ...
P-selectin glycoprotein ligand-1 (PSGL-1) is a dimeric, mucin-like, 120-kDa glycoprotein that binds to P-, E-, and L-selectins. PSGL-1 is expressed primarily on the surface of lymphoid and myeloid ...
Given that HIV-protease inhibitors (HIV-PIs) are substrates/inhibitors of the multidrug transporter ABCB1, can induce ABCB1 expression, and are used in combination with doxorubicin for AIDS-Kaposi's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback